Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

REVB

Revelation Biosciences (REVB)

Revelation Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REVB
DateTimeSourceHeadlineSymbolCompany
07/19/20244:02PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
06/24/20249:00AMBusiness WireRevelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker ActivityNASDAQ:REVBRevelation Biosciences Inc
06/13/20249:21AMBusiness WireRevelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
05/10/20244:52PMBusiness WireRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024NASDAQ:REVBRevelation Biosciences Inc
03/22/20244:15PMBusiness WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023NASDAQ:REVBRevelation Biosciences Inc
03/13/20249:00AMBusiness WireRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
03/12/20249:00AMBusiness WireRevelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth ConferenceNASDAQ:REVBRevelation Biosciences Inc
03/04/20249:00AMBusiness WireRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
02/13/20248:12PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
02/13/20249:00AMBusiness WireRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
02/12/202410:19AMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
02/08/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
02/05/20244:41PMBusiness WireRevelation Biosciences Inc. Announces Closing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
02/02/20244:06PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:REVBRevelation Biosciences Inc
02/01/20246:00AMBusiness WireRevelation Biosciences Inc. Announces Pricing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
02/01/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:REVBRevelation Biosciences Inc
01/30/20245:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
01/30/20243:32PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:REVBRevelation Biosciences Inc
01/30/20249:00AMBusiness WireRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
01/29/20245:32PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:REVBRevelation Biosciences Inc
01/23/20244:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
01/23/20249:00AMBusiness WireRevelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024NASDAQ:REVBRevelation Biosciences Inc
01/22/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
12/22/20235:06PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:REVBRevelation Biosciences Inc
12/22/20231:23PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
12/12/20234:59PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:REVBRevelation Biosciences Inc
11/13/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
11/13/20234:05PMBusiness WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023NASDAQ:REVBRevelation Biosciences Inc
11/09/20234:07PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REVBRevelation Biosciences Inc
10/12/20234:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:REVB